Navigation Links
Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
Date:9/18/2007

tements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in the Forest Laboratories' SEC reports, including the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2007 and quarterly report on form 10-Q for the period ended June 30, 2007.

References

1. Joos GF, Schelfhout VJ, Kanniess F et al. Bronchodilator effects of

aclidinium bromide, a novel long-acting anticholinergic, in COPD

patients: a phase II study. European Respiratory Society (ERS) Annual

Congress, September 2007. Poster.

2. Schelfhout VJ, Joos GF, Gil EG et al. Bronchodilator/bronchoprotective

effects of aclidinium bromide, a novel long-acting anticholinergic: a

phase I study. European Respiratory Society (ERS) Annual Congress,

September 2007. Poster.

3. Gavalda A, Miralpeix M, Ramos I et al. Aclidinium bromide, a novel

muscarinic receptor antagonist combining long residence at M3 receptors

and rapid plasma clearance. European Respiratory Society (ERS) Annual

Congress, September 2007. Poster.

4. Miralpeix M, Gavalda A, Morcillo E et al. Assessment of the potency and

duration of action of aclidinium bromide in guinea pig isolated trachea

in vitro. European Respiratory Society (ERS) Annual Congress, September

2007. Poster.

5. Global Initiative for Chronic Obstructive Lung Disease. Global strategy

for the diagnosis, management, and prevention of chronic obstructive

pulmonary disease; MCR Vision, Inc.; 2006

6. CDC, http://www.cdc.gov/nceh/airpollution/copd/copdfaq.htm, accessed

Sept
'/>"/>

SOURCE Forest Laboratories
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to announce the ... new Chief Executive Officer.  Mark was promoted from his current ... the company,s four facilities in Massachusetts , ... joined Tegra Medical in 2012 with 20+ years of broad-based ...
(Date:1/15/2014)... The Cadence Fitness & Health Center has been ... Fitness Association, a non-profit organization assisting medically integrated health ... Cadence Fitness & Health Center is the only certified ... the Chicagoland area. "The certification means the ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
(Date:7/9/2014)... from Montefiore Medical Center and the ... will present new findings at the Alzheimer,s Association International ... in Copenhagen, Denmark. Data from the four abstracts will ... normality to mild cognitive impairment and dementia. The research ... established in 1980 to examine healthy brain aging as ...
(Date:7/9/2014)... a reputation for being highly toxic, but when used in ... found to offer potential health benefits in a range of ... new compound (AP39), designed and made at the University of ... delivery of very small amounts of the substance to the ... Exeter have already found that the compound protects mitochondria ...
(Date:7/9/2014)... (July 9, 2014) A retrospective study conducted by ... colleagues reports that among adults with intellectual and developmental ... number of years receiving dental care increased. The findings, ... in Dentistry , may help improve interventions designed to ... , The researchers reviewed the dental records of ...
(Date:7/9/2014)... , , , , , ... , , , , ... SA80 assault rifle and the microphone is 50m downrange from the firer and approximately 30cm from the bullet... , ... , , , , , ... , , , , , ...
(Date:7/9/2014)... Medicine of the University of Southern California (USC) ... of the immune system are completely resistant to ... discovery suggests that blocking this immune system component ... hyper-inflammatory diseases such as rheumatoid arthritis and Type ... on June 23 in The Journal of ...
Breaking Medicine News(10 mins):Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7
... danger rises if the drugs are used with certain ... -- Antidepressant drugs called selective serotonin reuptake inhibitors (SSRIs), ... the risk of gastrointestinal bleeding, and the threat is ... and similar pain medications at the same time as ...
... Nurses Gain Stronger Voice for Patient Care, AUGUSTA, ... Center in Bangor, Maine appears to be over -- ... Registered nurses and hospital officials Thursday night reached ... the nurses say will,substantially enhance their voice in patient ...
... TO COMMENT ON THE MARKET FORECAST FOR THE DRUG, ... Ph.D., analyst,at Decision Resources, is available to discuss the ... of Merck,s Isentress, the,first integrase inhibitor drug which blocks ... new cells. Integrase inhibitors are a novel class ...
... New products, a growing world,population expected to reach ... the,aging of that population, will push anesthesia drug ... to Anesthesia Drugs: Worldwide Markets, a,new report by ... procedures required anesthetic,administration worldwide in 2006, and Kalorama ...
... Stryker Corporation,(NYSE: SYK ) disclosed today ... made an informal inquiry of the Company regarding ... connection with the sale,of medical devices in certain ... Securities and Exchange Commission regarding this,informal investigation. ...
... the 118 patients with portal vein thrombosis, noncirrhotic and ... with well tolerated bleed. Cirrhosis and tumor related portal ... Hypercoagulable state as a cause of portal vein thrombosis ... largest number of patients. , A research article to ...
Cached Medicine News:Health News:Antidepressants Boost GI Bleeding Risk 2Health News:MSNA: Strike Averted - Tentative Pact at EMMC 2Health News:Impending FDA Approval Decision on the First HIV Integrase Inhibitor Can Have Significant Impact for Patients 2Health News:Anesthesia Drugs Market to Grow to $4.3 Billion by 2011 as Populations and Uses for Anesthesia Increase 2Health News:Portal vein thrombosis is common in extraportal vein obstruction 2
... throughput reading of entire racks. Its scanner-based image ... and reads in approximately 10 seconds per rack. ... and a list of ActiveX controls is provided ... includes a USB HP Scanner and software. Compatible ...
... with powder-coated steel legs. Height ... in hundreds of sizes and ... light fixtures and ionizing equipment. ... custom building to meet special ...
Round, height-adjustable, steel laboratory stools with small footprint for small spaces • Choose options like different height-adjustment mechanism or paint finish. • your choice of color...
... This BioSafe room is configured specifically ... and chemical analysis. Panels are precision-joined ... easy to wipe down and disinfect. ... double-wall panel design creates strong, rigid ...
Medicine Products: